Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Summary

This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma patients. The primary objective is to determine the efficacy of Elranatamab in patients with previously untreated high-risk SMM. The key-secondary objective is to determine the safety of Elranatamab in patients with previously untreated high-risk SMM.

Timeline

Start

2024-05-14

Primary completion

2027-07

Completion

2031-07

Drugs

Indications